Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

Brilaroxazine hydrochloride is under clinical development by Reviva Pharmaceuticals and currently in Phase I for Major Depressive Disorder.

Here’s a look at the best and worst states in each of our four data categories: mental health provider ratio, percentage of ...

INR:7343. chunk base seed map Biogen to develop breakthrough depression and movement disorder treatments with $3.1 billion in R&D collaboration The era of cen ...

People explore different treatments and therapies to help with depression, and recently, researchers wanted to understand if ...

White matter alterations within the brain are associated with cognitive impairment among individuals with and without major ...

A groundbreaking clinical trial has revealed that nerve-stimulating therapy can bring significant improvements to people with ...

Learn why we need vitamin D to manage symptoms of Seasonal Affective Disorder, and why more research is needed.

TMS has been approved for treating clinical depression in adults since 2008. Recent effectiveness data with adolescents shows ...

Neumora Therapeutics to release phase 3 data on Navacaprant for MDD treatment in 2024. Check out NMRA's catalysts that might ...

P rogress in addressing mental health is notoriously slow and mostly incremental. Breakthrough treatments tend to be rare, ...

The following is a summary of “Service coverage for major depressive disorder: estimated rates of minimally adequate ...